Pyridostigmine

Category: pharmacological

Aliases: Mestinon

Pharmacological Mechanism

Reversible peripheral acetylcholinesterase inhibitor — quaternary ammonium prevents BBB penetration → no CNS effects. First-line symptomatic therapy for myasthenia gravis. Cholinergic crisis at overdose; nicotine-receptor desensitization under-treats severe cases.

Half-Life (t½)

PO: 3.5h, IV: 1.62h

Dosing Guidelines

• PO: Typical 60mg (Range: 30 - 600 mg)

Target Organ Systems

• nervous